149 related articles for article (PubMed ID: 31512500)
1. Devimistat in combination with high dose cytarabine and mitoxantrone compared with high dose cytarabine and mitoxantrone in older patients with relapsed/refractory acute myeloid leukemia: ARMADA 2000 Phase III study.
Pardee TS; Luther S; Buyse M; Powell BL; Cortes J
Future Oncol; 2019 Oct; 15(28):3197-3208. PubMed ID: 31512500
[TBL] [Abstract][Full Text] [Related]
2. A Phase I Study of CPI-613 in Combination with High-Dose Cytarabine and Mitoxantrone for Relapsed or Refractory Acute Myeloid Leukemia.
Pardee TS; Anderson RG; Pladna KM; Isom S; Ghiraldeli LP; Miller LD; Chou JW; Jin G; Zhang W; Ellis LR; Berenzon D; Howard DS; Hurd DD; Manuel M; Dralle S; Lyerly S; Powell BL
Clin Cancer Res; 2018 May; 24(9):2060-2073. PubMed ID: 29437791
[No Abstract] [Full Text] [Related]
3. Phase II trial of cytarabine and mitoxantrone with devimistat in acute myeloid leukemia.
Anderson R; Miller LD; Isom S; Chou JW; Pladna KM; Schramm NJ; Ellis LR; Howard DS; Bhave RR; Manuel M; Dralle S; Lyerly S; Powell BL; Pardee TS
Nat Commun; 2022 Mar; 13(1):1673. PubMed ID: 35354808
[TBL] [Abstract][Full Text] [Related]
4. Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
Thiel A; Schetelig J; Pönisch W; Schäfer-Eckart K; Aulitzky W; Peter N; Schulze A; Maschmeyer G; Neugebauer S; Herbst R; Hänel A; Morgner A; Kroschinsky F; Bornhäuser M; Lange T; Wilhelm M; Niederwieser D; Ehninger G; Fiedler F; Hänel M; ;
Ann Oncol; 2015 Jul; 26(7):1434-40. PubMed ID: 25922062
[TBL] [Abstract][Full Text] [Related]
5. A Phase III open-label trial to evaluate efficacy and safety of CPI-613 plus modified FOLFIRINOX (mFFX) versus FOLFIRINOX (FFX) in patients with metastatic adenocarcinoma of the pancreas.
Philip PA; Buyse ME; Alistar AT; Rocha Lima CM; Luther S; Pardee TS; Van Cutsem E
Future Oncol; 2019 Oct; 15(28):3189-3196. PubMed ID: 31512497
[TBL] [Abstract][Full Text] [Related]
6. Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.
Chevallier P; Delaunay J; Turlure P; Pigneux A; Hunault M; Garand R; Guillaume T; Avet-Loiseau H; Dmytruk N; Girault S; Milpied N; Ifrah N; Mohty M; Harousseau JL
J Clin Oncol; 2008 Nov; 26(32):5192-7. PubMed ID: 18854573
[TBL] [Abstract][Full Text] [Related]
7. Clofarabine, cytarabine, and mitoxantrone in refractory/relapsed acute myeloid leukemia: High response rates and effective bridge to allogeneic hematopoietic stem cell transplantation.
Gill H; Yim R; Pang HH; Lee P; Chan TSY; Hwang YY; Leung GMK; Ip HW; Leung RYY; Yip SF; Kho B; Lee HKK; Mak V; Chan CC; Lau JSM; Lau CK; Lin SY; Wong RSM; Li W; Ma ESK; Li J; Panagiotou G; Sim JPY; Lie AKW; Kwong YL
Cancer Med; 2020 May; 9(10):3371-3382. PubMed ID: 32187883
[TBL] [Abstract][Full Text] [Related]
8. A Phase I/II Trial of MEC (Mitoxantrone, Etoposide, Cytarabine) in Combination with Ixazomib for Relapsed Refractory Acute Myeloid Leukemia.
Advani AS; Cooper B; Visconte V; Elson P; Chan R; Carew J; Wei W; Mukherjee S; Gerds A; Carraway H; Nazha A; Hamilton B; Sobecks R; Caimi P; Tomlinson B; Malek E; Little J; Miron A; Pink J; Maciejewski J; Unger A; Kalaycio M; de Lima M; Sekeres MA
Clin Cancer Res; 2019 Jul; 25(14):4231-4237. PubMed ID: 30992301
[TBL] [Abstract][Full Text] [Related]
9. Improved outcome of children with relapsed/refractory acute myeloid leukemia by addition of cladribine to re-induction chemotherapy.
Ruan M; Liu LP; Zhang AL; Quan Qi B; Liu F; Liu TF; Liu XM; Chen XJ; Yang WY; Guo Y; Zhang L; Zou Y; Chen YM; Zhu XF
Cancer Med; 2021 Feb; 10(3):956-964. PubMed ID: 33491298
[TBL] [Abstract][Full Text] [Related]
10. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
Narayan R; Blonquist TM; Emadi A; Hasserjian RP; Burke M; Lescinskas C; Neuberg DS; Brunner AM; Hobbs G; Hock H; McAfee SL; Chen YB; Attar E; Graubert TA; Bertoli C; Moran JA; Bergeron MK; Foster JE; Ramos AY; Som TT; Vartanian MK; Story JL; McGregor K; Macrae M; Behnan T; Wey MC; Rae J; Preffer FI; Lesho P; Duong VH; Mann ML; Ballen KK; Connolly C; Amrein PC; Fathi AT
Cancer; 2020 Mar; 126(6):1264-1273. PubMed ID: 31860140
[TBL] [Abstract][Full Text] [Related]
11. Single-dose mitoxantrone in combination with continuous infusion intermediate-dose cytarabine plus etoposide for treatment of refractory or early relapsed acute myeloid leukemia.
Lee SS; Lee JH; Lee JH; Kim DY; Kim SH; Lim SN; Lee YS; Seol M; Ryu SG; Kang YA; Jang S; Park CJ; Chi HS; Yun SC; Lee KH
Leuk Res; 2009 Apr; 33(4):511-7. PubMed ID: 18819710
[TBL] [Abstract][Full Text] [Related]
12. A phase I-II trial of escalating doses of mitoxantrone with fixed doses of cytarabine plus fludarabine as salvage therapy for patients with acute leukemia and the blastic phase of chronic myelogenous leukemia.
Koller CA; Kantarjian HM; Feldman EJ; O'Brien S; Rios MB; Estey E; Keating M
Cancer; 1999 Dec; 86(11):2246-51. PubMed ID: 10590364
[TBL] [Abstract][Full Text] [Related]
13. Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.
Wells RJ; Adams MT; Alonzo TA; Arceci RJ; Buckley J; Buxton AB; Dusenbery K; Gamis A; Masterson M; Vik T; Warkentin P; Whitlock JA;
J Clin Oncol; 2003 Aug; 21(15):2940-7. PubMed ID: 12885813
[TBL] [Abstract][Full Text] [Related]
14. Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study.
Bao Y; Zhao J; Li ZZ
Clin Transl Oncol; 2018 Jul; 20(7):870-880. PubMed ID: 29181696
[TBL] [Abstract][Full Text] [Related]
15. A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia.
Lancet JE; Roboz GJ; Cripe LD; Michelson GC; Fox JA; Leavitt RD; Chen T; Hawtin R; Craig AR; Ravandi F; Maris MB; Stuart RK; Karp JE
Haematologica; 2015 Feb; 100(2):231-7. PubMed ID: 25381131
[TBL] [Abstract][Full Text] [Related]
16. Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia.
Karp JE; Smith BD; Levis MJ; Gore SD; Greer J; Hattenburg C; Briel J; Jones RJ; Wright JJ; Colevas AD
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4467-73. PubMed ID: 17671131
[TBL] [Abstract][Full Text] [Related]
17. Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.
Halpern AB; Othus M; Huebner EM; Buckley SA; Pogosova-Agadjanyan EL; Orlowski KF; Scott BL; Becker PS; Hendrie PC; Chen TL; Percival MM; Estey EH; Stirewalt DL; Walter RB
Leukemia; 2017 Dec; 31(12):2560-2567. PubMed ID: 28555084
[TBL] [Abstract][Full Text] [Related]
18. A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia.
Wang AY; Weiner H; Green M; Chang H; Fulton N; Larson RA; Odenike O; Artz AS; Bishop MR; Godley LA; Thirman MJ; Kosuri S; Churpek JE; Curran E; Pettit K; Stock W; Liu H
J Hematol Oncol; 2018 Jan; 11(1):4. PubMed ID: 29304833
[TBL] [Abstract][Full Text] [Related]
19. Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen.
Sternberg DW; Aird W; Neuberg D; Thompson L; MacNeill K; Amrein P; Shulman LN
Cancer; 2000 May; 88(9):2037-41. PubMed ID: 10813714
[TBL] [Abstract][Full Text] [Related]
20. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia.
Uy GL; Rettig MP; Motabi IH; McFarland K; Trinkaus KM; Hladnik LM; Kulkarni S; Abboud CN; Cashen AF; Stockerl-Goldstein KE; Vij R; Westervelt P; DiPersio JF
Blood; 2012 Apr; 119(17):3917-24. PubMed ID: 22308295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
